Monday, November 9, 2026

USD/EUR Bullish Momentum: 0.795% Up In The Last 24 Hours

ViaNews Editorial Team

January 2, 2024

USD/EUR Bullish Momentum: 0.795% Up In The Last 24 Hours

(VIANEWS) - USD/EUR (USDEUR) has been up by 0.7953% for the last session's close. At 08:08 EST on Tuesday, 2 January, USD/EUR (USDEUR) is $0.91.

USD/EUR (USDEUR) Range

Regarding USD/EUR's daily highs and lows, it's 0.862% up from its trailing 24 hours low of $0.90 and 0.74% up from its trailing 24 hours high of $0.91.

USD/EUR's yearly highs and lows, it's 2.886% up from its 52-week low and 4.65% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.08%, a negative 0.07%, and a positive 0.35%, respectively.

USD/EUR's highest amplitude of average volatility was 0.32% (last week), 0.36% (last month), and 0.35% (last quarter), respectively.

News about

  • According to FXStreet on Tuesday, 2 January, "The latter should act as a key pivotal point, which if broken decisively could make the USD/JPY pair vulnerable to accelerate the fall towards the 139.35 region en route to the 139.00 mark, the 138.75 area and the 138.00 mark (July 28 low).", "The Japanese Yen (JPY) ticks lower against its American counterpart and lifts the USD/JPY pair beyond mid-142.00s amid lighter trading volumes during the Asian session on Monday. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com
USD/EUR Bullish Momentum: 0.795% Up In The Last 24 Hours | Via News